Compare Stocks → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DVAXNASDAQ:GTHXNASDAQ:KALANASDAQ:PRVBNASDAQ:RTRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDVAXDynavax Technologies$11.74+0.2%$12.14$10.57▼$15.15$1.54B1.32.12 million shs1.82 million shsGTHXG1 Therapeutics$4.49+1.1%$3.90$1.08▼$5.00$234.74M1.71665,254 shs574,426 shsKALAKALA BIO$7.01+3.7%$7.34$5.10▼$19.35$19.73M-1.7511,435 shs4,531 shsPRVBProvention Bio$24.98+3.1%$24.58$3.18▼$25.00$2.37B2.472.28 million shs9.12 million shsRTRXTravere Therapeutics$6.26+1.6%$26.56$8.98▼$24.96$319.59M0.67412,277 shs767,565 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDVAXDynavax Technologies+0.17%+4.73%-3.69%-7.92%+6.53%GTHXG1 Therapeutics+1.13%+12.53%-4.87%+6.65%+48.68%KALAKALA BIO+2.75%+8.47%-10.51%+0.68%-54.76%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%RTRXTravere Therapeutics+4.33%+19.01%-10.32%-26.27%-60.65%The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDVAXDynavax Technologies3.9642 of 5 stars3.41.00.04.70.02.51.9GTHXG1 Therapeutics4.062 of 5 stars3.35.00.03.82.00.80.6KALAKALA BIO4.1583 of 5 stars3.55.00.04.42.40.80.0PRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDVAXDynavax Technologies2.75Moderate Buy$25.00112.95% UpsideGTHXG1 Therapeutics2.50Moderate Buy$8.6793.02% UpsideKALAKALA BIO3.00Buy$18.00156.87% UpsidePRVBProvention BioN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest PRVB, GTHX, KALA, RTRX, and DVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2024GTHXG1 TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/1/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.004/12/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.004/2/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $21.004/1/2024KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.002/28/2024GTHXG1 TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $5.002/28/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.002/23/2024DVAXDynavax TechnologiesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/13/2024GTHXG1 TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$5.00 ➝ $4.002/13/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDVAXDynavax Technologies$232.28M6.61N/AN/A$4.81 per share2.44GTHXG1 Therapeutics$82.51M2.84N/AN/A$0.53 per share8.47KALAKALA BIO$3.89M5.07N/AN/A$2.79 per share2.51PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84RTRXTravere Therapeutics$175.34M1.82N/AN/A$5.15 per share1.22Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDVAXDynavax Technologies-$6.39M-$0.06N/A27.30N/A-2.75%-1.08%-0.66%5/8/2024 (Confirmed)GTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-36.40%-74.75%-24.25%8/7/2024 (Estimated)KALAKALA BIO-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/ARTRXTravere Therapeutics-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/ALatest PRVB, GTHX, KALA, RTRX, and DVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/ADVAXDynavax Technologies-$0.04N/A+$0.04N/AN/AN/A 5/1/2024Q1 2024GTHXG1 Therapeutics-$0.19-$0.20-$0.01-$0.20$15.21 million$14.48 million 3/29/2024Q4 2023KALAKALA BION/A-$3.18-$3.18-$3.18N/AN/A2/28/202412/31/2023GTHXG1 Therapeutics-$0.27-$0.21+$0.06-$0.21$12.83 million$14.87 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDVAXDynavax TechnologiesN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDVAXDynavax Technologies0.4113.8112.96GTHXG1 Therapeutics1.342.943.45KALAKALA BIO5.106.336.33PRVBProvention Bio0.191.931.92RTRXTravere Therapeutics0.667.237.14OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDVAXDynavax Technologies96.96%GTHXG1 Therapeutics24.21%KALAKALA BIO24.61%PRVBProvention Bio37.39%RTRXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipDVAXDynavax Technologies2.98%GTHXG1 Therapeutics8.23%KALAKALA BIO13.40%PRVBProvention Bio13.10%RTRXTravere Therapeutics4.63%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDVAXDynavax Technologies408130.86 million126.96 millionOptionableGTHXG1 Therapeutics10052.28 million48.00 millionOptionableKALAKALA BIO432.82 million2.44 millionNot OptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableRTRXTravere Therapeutics22151.05 millionN/ANot OptionablePRVB, GTHX, KALA, RTRX, and DVAX HeadlinesSourceHeadlineCritical Insights From Travere Therapeutics Analyst Ratings: What You Need To Knowmarkets.businessinsider.com - April 17 at 4:04 PMTravere Therapeutics price target lowered by $3 at H.C. Wainwright, here's whyrealmoney.thestreet.com - February 23 at 3:07 PMTravere Therapeutics gains as EU backs kidney disease therapymsn.com - February 23 at 8:37 AMNew Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?msn.com - February 21 at 8:05 AMTravere Therapeutics price target raised by $4 at Citi, here's whyrealmoney.thestreet.com - February 17 at 7:51 AMTravere Therapeutics: Hold Rating Amidst Filspari’s Steady Performance and Emerging Market Competitionmarkets.businessinsider.com - February 16 at 10:57 AMEarnings Preview For Travere Therapeuticsbenzinga.com - February 14 at 4:00 PMTravere Therapeutics: A Strong Buy on Filspari’s Outperformance and Promising Market Prospectsmarkets.businessinsider.com - January 11 at 7:54 AMOptimistic Outlook for Travere Therapeutics Amid FDA Developments and Strategic Reorganizationmarkets.businessinsider.com - December 7 at 5:53 PMTravere (TVTX) Up on Latest Portfolio Updates & Reorganizationmsn.com - December 6 at 5:04 PMBuy Rating for Travere Therapeutics: Optimism Fueled by Regulatory Prospects and Strategic Reorganizationmarkets.businessinsider.com - December 5 at 8:07 PMTravere Therapeutics upgraded to Buy from Neutral at Citirealmoney.thestreet.com - December 5 at 2:51 PMTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU Treatmentsmarketwatch.com - December 4 at 8:55 PMTravere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conferencebenzinga.com - November 21 at 6:25 PMPromising Sales Performance and Growth Prospects Solidify Buy Rating for Travere Therapeuticsmarkets.businessinsider.com - November 8 at 3:32 PMPreview: Travere Therapeutics's Earningsbenzinga.com - November 6 at 2:56 PMTravere Therapeutics Inc Ordinary Shares TVTXmorningstar.com - October 31 at 6:21 PMWedbush Reiterates Travere Therapeutics (TVTX) Outperform Recommendationmsn.com - September 30 at 10:26 AMWhy Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Lowmsn.com - September 22 at 5:07 PMWhy Shares of Travere Therapeutics Are Slumping Thursdaymsn.com - September 21 at 3:15 PMBack To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challengesmarkets.businessinsider.com - September 21 at 3:15 PMBank of America Securities Remains a Buy on Travere Therapeutics (TVTX)markets.businessinsider.com - August 31 at 7:43 AMMirum Pharmaceuticals to Buy Bile Acid Product Portfolio from Travere Therapeuticsmarketwatch.com - July 19 at 8:02 PMTVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities Lawsbenzinga.com - June 26 at 8:57 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsDynavax TechnologiesNASDAQ:DVAXDynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.G1 TherapeuticsNASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.KALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Provention BioNASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Travere TherapeuticsNASDAQ:RTRXTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.